NASDAQ:NRGN

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
····

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares closed at $26.95 Wednesday, up 0.3%, with little movement before Thursday’s Nasdaq open. About 90% of participants have been dosed in the registrational Embolden trial for NGN-401, with completion expected in Q2. Neurogene reported $243.2 million in cash as of March 31, enough to fund operations into early 2028. The company’s latest filings were posted May 12, with no new updates since.
May 21, 2026

Stock Market Today

  • 6 Key Numbers to Value Pro Medicus Ltd (ASX:PME) Shares
    May 30, 2026, 1:15 AM EDT. Pro Medicus Ltd (ASX:PME), a radiology IT software provider, has seen its share price fall 40.59% since the start of the year. The company posted $162 million in annual revenue with a 33.4% compound annual growth rate over three years. Its gross margin of 99.8% highlights operational strength. PME reported a profit of $83 million last year, growing at 39.0% CAGR over three years. Financial health is robust, with net debt of negative $153 million, indicating more cash than debt, and a low debt-to-equity ratio of 1.1%. The return on equity (ROE) stands at 50.7%, reflecting efficient capital use. These metrics provide key insights to evaluate PME's share performance this year amid market volatility.